Skip to main content
Article thumbnail
Location of Repository

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

By Caterina Guinovart, John J. Aponte, Jahit Sacarlal, Pedro Aide, Amanda Leach, Quique Bassat, Eusébio Macete, Carlota Dobaño, Marc Lievens, Christian Loucq, W. Ripley Ballou, Joe Cohen and Pedro L. Alonso
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2666156
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1997). A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria.
    2. (2008). Antibodies to Pre-erythrocytic Plasmodium falciparum Antigens and Risk of Clinical Malaria in Kenyan Children.
    3. (1994). Attributable fraction estimates and case definitions for malaria in endemic areas.
    4. (2005). Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
    5. (2001). Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
    6. (2008). Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
    7. (2001). Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    8. (2004). Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
    9. (1995). Graphical methods for assessing violations of the proportional hazards assumption in Cox regression.
    10. (2007). How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions?
    11. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.
    12. (2001). Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana.
    13. (2005). Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial.
    14. (2003). Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhica district.
    15. (2007). Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.
    16. (2007). Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine.
    17. (2000). Modeling survival data: extending the Cox model.
    18. (1999). Plasmodium chabaudi chabaudi: effect of low parasitaemias on immunity in CB6F1 mice.
    19. (1987). Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.
    20. (2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.
    21. (1994). Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.
    22. (2008). Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    23. (2007). Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/ IIb trial.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.